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Abstract
Porcine endogenous retroviruses (PERV) are considered an obstacle to the safe use of cells, tissues, and organs from pigs in the course
of xenotransplantation. Thus, the detection of viral proteins and of a potential PERV infection is of major interest. Recently, we have
published the generation of a highly specific antiserum directed against the nucleocapsid (p10) of PERV (Xenotransplantation 7 (2000),
221). Here we present new peptide-antisera specific to the capsid protein (p30) and the surface molecule of PERV class B (SU, gp70(B))
as well as the transmembrane moiety of the envelope protein (TM, p15E) of PERV which showed functionality in several immunological
assays, such as immunoblots, immunofluorescence, and immunogold staining. Thus, these antisera can be used as tools for the identification
of viral proteins in basic research as well as clinical trials.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Recent studies utilizing NOD/SCID mice have shown
that Porcine endogenous retrovirus (PERV) particles were
released from transplanted porcine islet cells and that sev-
eral organs of the recipients were productively infected with
PERV (van der Laan et al., 2000). So far, retrospective
investigations of patients that had received life porcine
tissue for therapeutic reasons have not shown any evidence
of PERV infection in vivo in humans (Patience et al., 1998;
Heneine et al., 1998; Paradis et al., 1999; Pitkin and Mullon,
1999; Dinsmore et al., 2000). On the other hand, in vitro
data show that primary porcine cells with and without mi-
togenic stimulation release PERV particles that are infec-
tious for human cells (Wilson et al., 1998, 2000; Martin et
al., 1998; van der Laan et al., 2000) and that primary human
endothelic cells could be infected productively with PERV
(Martin et al., 2000). In contrast to previous pseudotype
experiments (Takeuchi et al., 1998), recent investigations
revealed that in addition to several human cell lines, cells
from nonhuman primates are susceptible to PERV (Blusch
et al., 2000). Furthermore, it was reported that PERV after
passaging on human cells are resistant to human comple-
ment (Patience et al., 1997) and that the resulting viruses
cross-package Moloney murine leukemia virus (MLV) vec-
tors (Wilson et al., 2000). Hence, even if the NOD/SCID
mouse model is not identical to the situation in an immu-
nocompromised human recipient of xenotransplants, these
findings together with the in vitro data suggest that a close
monitoring of potential viral expression in recipients should
be performed. To this end, immunologic assays utilizing
specific antibodies directed against PERV are instrumental.
Results and discussion
Peptides used for immunization
An immunogenic sequence of PERV Gag was selected
based on the sequence of molecular clone PERV-B(33)
(Czauderna et al., 2000). Sequences with immunogenic po-
tential of both xenotropic classes of PERV Env, Env-A and
Env-B, were selected based on the sequences of molecular
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clones PERV-B(33) and PERV-A(42) (Czauderna et al.,
2000; Krach et al., 2001). The peptide sequences derived
from Gag p30 (capsid) and from Env p15E (TM) were used
for immunization of rabbits and the peptide sequence de-
rived from Env gp70(B) (SU) was used for immunization of
chickens. The peptide positions in the corresponding pro-
teins are shown in Table 1. Chickens were also used for the
generation of anti-()-sera against a peptide derived from
the SU moiety of PERV Env-A. However, the resulting
serum showed no reactivity in immunoassays (data not
shown).
Gag-specific antiserum
The initial test of the PERV Gag -serum was performed
by Western blot analyses using lysates of human cells that
produce PERV and sucrose cushion purified PERV parti-
cles. As shown in Fig. 1A, the -p30 serum specifically
reacted with proteins in lysates of 293/PERV-B(33) cells
and 293 PERV-PK cells and with proteins derived from
virus particles (Fig. 1A, lanes 2, 3, and 4). In PERV-
producing cells signals were obtained for the Gag polypro-
tein (60 kDa), the mature capsid protein (30 kDa), and an
intermediate cleavage product of 40 kDa (Fig. 1A, lanes 2
and 3). In addition a minor signal was obtained for the
Gag–Pol precursor with an apparent mass of 180 kDa
(p180gag-pol), which is synthesized in an approximately 20-
fold lower amount than the remaining proteins as it has been
described for MLV (Dickson et al., 1984). This band pattern
largely corresponds to the pattern described previously for
PERV Gag p10 antiserum (Krach et al., 2000) except that
due to the immunogen the Gag -p30 serum revealed a band
for the mature capsid (Fig. 1A, lanes 2, 3, and 4), indicating
that budding viruses have converted from immature to ma-
ture C-type structure. The lack of the 40-kDa intermediate
in purified virus particles (Fig. 1A, lane 4) is due to the
conversation process during the viral budding. Since the
Gag polyprotein is cleaved by the viral proteases during
viral maturation, protease-containing particles should con-
tain mainly the cleavage end-product p30. Immature parti-
cles, indicated by the existence of Gag polyproteins, have
been described to be deficient in the viral protease (Dickson
et al., 1984). An additional band of 55 kDa was detected in
purified virus particles (Fig. 1A, lane 4). It may be specu-
lated that this protein represents another cleavage interme-
diate of p60 as it has been described as a second cleavage
pathway for MLV (Dickson et al., 1984); however, there is
no experimental proof yet. Analyses have suggested that the
cleavage site between p10 and p30 might be recognized by
cellular proteases (Dickson et al., 1984) explaining the ex-
istence of p55 in protease-deficient, immature particles.
Interestingly, no putative band with an apparent molecular
mass of 70 kDa could be detected with the p30 antiserum
after glycosidase treatment (data not shown) in cell lysates
Table 1
PERV peptide sequences used for immunizations
Peptide name Part of polyprotein aa position aa sequence
p30 Capsid 327–340 H2N-LRG ASR RPT NLA KVC-CONH2
gp70(B) SU-Env 250–264 H2N-PAL EPP HNL PVP QLT C-CONH2
p15E TM-Env 641–657 H2N-VLR QQY QGL LSQ GET DL-COOH
Note. Aminoterminal cysteine residues (C, in italics) were added for coupling to the carrier molecule prior to immunization of rabbits (p30 and p15E) and
chickens (gp70(B)). All peptide antibodies are derived from clone PERV-B(33) (Czauderna et al., 2000; Acc. No. AJ133816).
Fig. 1. Immunoblot analyses of untransfected 293 cells (lanes 1, 5, and 9), 293 cells transfected with the molecular clone PERV-B(33) (293/PERV-B(33),
lanes 2, 6, and 10), PERV-producing human cells (293 PERV-PK, lanes 3, 7, and 11), and PERV particles (lanes 4, 8, and 12). (A) PERV Gag p30 antiserum,
(B) Env gp70(B) (SU) antiserum, (C) PERV Env p15E (TM) antiserum. Arrows indicate (A) the Gag polyprotein (60 kDa), an intermediate form consisting
of the capsid and the nucleocapsid protein (p30 and p10; 40 kDa), and the mature capsid protein (30 kDa); open arrow indicates the Gag–Pol precursor (180
kDa); (B) the Env precursor (80 kDa), and the mature gp70 (70 kDa); open arrow indicates an unidentified polyprotein in PERV particles (90 kDa); (C) the
Env precursor (80 kDa), the immature TM moiety of Env (20 kDa), and the mature p15E (17 kDa); open arrow indicates R-peptide-related remnants (26 kDa)
in particles (lane 12). Sizes are indicated in kilodaltons.
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of PERV-producing cells (Fig. 1A, lanes 2 and 3), whereas
such a protein representing the glycosylated form of Gag
has been described for MLV (Dickson et al., 1984). No
bands of corresponding sizes were revealed using lysates of
untransfected 293 cells (Fig. 1A, lane 1). Likewise, the p30
preimmune serum showed no reactivity with PERV parti-
cles or lysates of PERV-producing cells (data not shown).
In addition to the immunoblot analyses, specific immu-
nofluorescence (IF) signals were revealed with the -p30
serum in PERV-producing human cells, where a pattern
similar to that described for the antiserum directed against
the nucleocapsid p10 in 293 PERV-PK cells and 293/
PERV-B(33) cells was found (Krach et al., 2000; Figs. 2A
and D). No signals were obtained on untransfected 293 cells
(data not shown). Furthermore, the Gag -p30 serum as
well as the previously described Gag p10 antiserum re-
vealed specific immunoreactions in 293/PERV-B(33) cells
(Czauderna et al., 2000) using immunogold staining meth-
ods (Figs. 3A and B). Corresponding to the Gag p10 anti-
serum, the -p30 serum showed reactivity in immune per-
oxidase assays (IPAP) in PERV-producing human cells
(data not shown).
As a high degree of homology exists in the amino acid
(aa) sequence of p30 used for immunization compared to
other C-type viruses, e.g., gibbon ape leukemia virus
(GaLV) and feline leukemia virus (FeLV) (Fig. 4), cross-
reactivity cannot be excluded. Thus, we tested putative
cross-reactivity of the -p30 serum in immunoblots using
cell culture supernatant containing murine leukemia virus
(MLV). No signals were obtained (data not shown). Since
the gag gene of the three PERV classes A, B, and C shows
homologies of more than 96%, it is conceivable that the
-p30 serum can be used to detect these classes, particularly
as no aa exchanges exist in the sequence used for immuni-
zation (data not shown).
Env-specific antisera
Antiserum against Env gp70(B)
For lysates of 293/PERV-B(33) cells (Czauderna et al.,
2000) and 293 PERV-PK cells (Fig. 1B, lanes 6 and 7), the
-gp70(B) serum revealed two bands with apparent molec-
ular masses of 80 and 70 kDa, corresponding to the putative
Env precursor (gp80), consisting of SU and TM, and the
mature SU moiety (gp70), respectively. Consequently, a
signal for gp70 was obtained when PERV particles were
investigated (Fig. 1B, lane 8). Interestingly, instead of the
putative gp80 protein, a band with an apparant molecular
mass of 90 kDa was observed in virions which could not be
detected in infected cells. This obvious shift from the gp80
to the gp90 protein suggests further modification of Env
after budding of particles. We are currently investigating
this aspect.
As described for MLV, the sugar residues of SU account
for 30% of the molecular mass of SU (Dickson et al., 1984).
Thus, the molecular mass of SU of PERV with a polypep-
tide core of 51 kDa would be approximately 71 kDa which
is consistent with the Western blot result.
As for -p30, the -gp70(B) serum showed no reactivity
with MLV, indicating its specificity for PERV (data not
shown), and there was no cross-reactivity with untrans-
fected 293 cells (Fig. 1B, lane 5). Furthermore, the gp70(B)
preimmune serum showed no reactivity with PERV parti-
cles or lysates of PERV-producing human cells (data not
shown).
Specific IF signals were obtained with -gp70(B), re-
vealing membrane-associated fluorescence signals (Fig.
2B). Likewise, no signals were obtained after incubation of
PERV-producing human cells with the corresponding pre-
immune serum (data not shown) or of untransfected 293
cells incubated with the -gp70(B) serum (Fig. 2H). No
Fig. 2. Indirect immunofluorescence analyses of 293 PERV-PK cells (panels A, B, C, F, and G), of untransfected 293 cells (panel H), and of 293/PERV-B(33)
cells (panels D and E). Panels A and D, -p30 serum; panels F and G, pre-p30 serum (panel G phase-contrast exposure of the same area as shown in panel
F); panels B and H, Env -gp70(B) serum; panels C and E, Env -p15E serum. Bar indicates 20 m.
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immunogold stainings of PERV-producing cells were per-
formed using -gp70(B) serum.
-gp70(B) serum is capable of inhibition of Env-B but
not Env-A pseudotyped vectors in vitro (Fig. 6). This spe-
cific inhibition of a virus class is due to sterical interference
as all native effectors of immune response are missing in
cell culture, i.e., no immune cells are present and comple-
ment has been heat inactivated. Therefore, we assume that
antibodies raised in patients planned to receive a xenotrans-
plant may be even more effective, since they could recruit
additional help from a suppressed but partially functional
immune system.
Antiserum against Env p15E
Incubation of lysates of 293/PERV-B(33) cells or 293
PERV-PK cells with the -p15E serum revealed bands with
apparent molecular masses of 90, 80, 20, and 17 kDa (Fig.
1C, lanes 10 and 11). The 80-kDa band corresponds to the
putative Env precursor (gp80) as detected with the
-gp70(B) serum (Fig. 1B, lanes 6 and 7). The 20-kDa
product corresponds to the putative TM moiety of PERV
Env which has been calculated to be 22 kDa in MLV
(Dickson et al., 1984). The immature p15E is cleaved during
the maturation of the virus particle by the viral protease,
releasing the R-peptide and leading to the mature p12E (Fig.
Fig. 3. Immunogold staining of ultrathin cryosections of PERV particles produced by 293/PERV-B(33) cells. (A) PERV Gag -p30 serum, (B) PERV Gag
-p10 serum, (C) PERV Env -p15E serum. Immunoreactions of proteins are visible as black dots on clusters of PERV particles. Bar indicates 250 nm.
Fig. 4. Comparison of amino acid homologies of the capsid protein of different C-type retroviruses. The gray box indicates the sequence of the peptide used
for immunization. Hatched and open boxes indicate neutral and nonneutral exchanges, respectively. Numbers above the first and last aa indicate the position
in the different Gag polyproteins.
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5A; Yang and Compans, 1996). Thus, the detected imma-
ture TM of 20 kDa indicates the existence of immature virus
particles similar to the p40 intermediate for Gag. However,
as the peptide used to raise the p15E antiserum comprises
the last 17 aa of PERV Env, i.e., the putative R-peptide of
PERV (Fig. 5A), the lower band of 17 kDa observed in
immunoblots (Fig. 1C, lanes 10 and 11) does not correspond
to the mature p12E but rather to another fusion product of
the R-peptide. The observed 90-kDa protein represents a
cross-reaction, since a band of similar size was present in
untransfected 293 cells after incubation with the p15E an-
tiserum (Fig. 1C, lane 9).
Consequently, no corresponding proteins were obtained
when purified PERV particles were analyzed with the
-p15E serum (Fig. 1C, lane 12); however, there was a band
of approximately 26 kDa. If immature virus particles are
deficient for the viral protease as described for MLV (Dick-
son et al., 1984), immature p15E should be detectable. A
possible reason are remnants of R-peptide fusions that are
detected by the p15E antiserum. For the TM of Rous sar-
coma virus (RSV), the stability of TM oligomers under
reducing conditions has been described (Einfeld, 1996).
There is no further cross-reactivity of the -p15E serum
with untransfected 293 cells except the described one of 90
kDa (Fig. 1C, lane 9). The p15E preimmune serum showed
no reactivity with PERV particles or lysates of PERV-
producing cells (data not shown).
Likewise, no cross-reactivity with MLV was found for
the -p15E serum, as anticipated by the low degree of
homology (68%) of the corresponding R-peptides (data not
shown and Fig. 5B).
Corresponding to the gp70(B) antiserum, the -p15E
serum revealed membrane-associated IF signals (Figs. 2C
and E). Furthermore, like Gag p30 and p10 antisera, the Env
p15E antiserum was tested for functionality using immuno-
gold staining methods, revealing specific immunoreactions
in 293/PERV-B(33) cells (Czauderna et al., 2000; Fig. 3C).
In addition, the p15E antiserum showed reactivity in IPAP
in PERV-producing human cells (not shown).
-p15E serum induced a weak neutralizing effect on
Env-B but not Env-A pseudotyped vectors (Fig. 6); more-
over, no reactivity is expected as the R-peptide should not
be present in virus particles. The observed reactivity of
approximately 5%, although reproducible, is barely signif-
icant. Therefore, we conclude that the effect may be due to
some unspecific interaction between Env-B pseudotypes
and -p15E serum which is also observed in Fig. 1C, lane
12, and discussed above.
Conclusion
In summary, we describe the development and experi-
mental evaluation of three new specific antisera directed
against the Gag capsid protein (p30), the Env class B sur-
face molecule (gp70(B)), and the transmembrane moiety of
Env (p15E) of PERV. The antisera showed specificity in
different immunoassays, including Western blot and IF
analyses, immune peroxidase assays (data not shown), and
immunogold stainings, although some proteins detected in
Western blot analyses need further investigation and a
cross-reactivity was revealed with the p15E antiserum.
Thus, the antisera described here represent specific tools for
laboratory use and for screening and monitoring purposes of
biological materials in the course of xenotransplantation, in
addition to the Gag -p10 serum described previously
(Krach et al., 2000).
Fig. 5. Sequence of p15E of PERV (A) and comparison of the amino acids of the R-peptide of PERV and MoMLV (B). (A) The putative fusion peptide (gray
box) and the putative membrane spanning domain (open box) are indicated (Einfeld, 1996). The sequence of the peptide used for immunization is underlined.
The arrow indicates the putative cleavage site between p15E and the R-peptide (Rein et al., 1994). (B) R-peptide homologies are indicated by open and
hatched boxes, respectively. Numbers above the first and last aa indicate the position in the different Env precursor proteins.
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Materials and methods
Cells and antisera
The 293 human embryonic kidney cells (ECACC, no.
85120602) and 293 cells that constitutively produce PERV
(293 PERV-PK) were kindly provided by Dr. Weiss, Lon-
don. In addition, 293 cells transfected with the molecular
clone PERV-B(33) (293/PERV-B(33); Czauderna et al.,
2000) producing infectious virions were used.
The antisera against PERV p30 and p15E were raised as
described previously (Krach et al., 2000) by Eurogentec
(Belgium). The gp70(B) antigen was synthesized by Sigma
ARK (Darmstadt). Polyclonal antisera were generated in
rabbits and chickens using complete Freund’s adjuvant in
case of the initial immunization and boost immunizations.
Indirect immunofluorescence microscopy
Indirect immunofluorescence analyses using PERV-pro-
ducing cells were carried out as described previously (Krach
et al., 2000). Secondary antibodies used were species-spe-
cific indocarbocyanin-conjugated anti-rabbit and anti-
chicken monoclonal antibodies (Dianova, Germany).
Immunoblotting
Western blot analyses using PERV-producing human
cells and PERV particles purified through sucrose cushions
were carried out as described previously (Krach et al.,
2000).
Immunogold staining of cryosections
Cells were grown and prepared as described elsewhere
(Krach et al., 2000). Sections of 0.1 m were obtained using
an Ultracut E (FC 4E, Reichert Jung) with a chamber tem-
perature of120°C and a cutter temperature of70°C. The
temperature of the embedded cells was 80°C. Polyclonal
goat anti-rabbit IgG (British Biocell) conjugated with
10-nm gold particles were used as secondary antibodies for
electron microscopy analyses.
Glycosylation analysis
The impact of glycosylation on the immunological de-
tection of Env proteins was determined by digestion of cell
lysates with N-glycosidase F (Roche) at 37°C for 20 h in the
presence of protease inhibitors.
Fig. 6. Effects of neutralizing antibodies directed against Env B sequences on transduction efficiency of PERV-A and PERV-B pseudotype vectors. (A)
Antibodies directed against Env gp70(B) (SU) or PERV Env p15E (TM) do not react with Env-A pseudotyped vectors. (B) Incubation of Env-B pseudotyped
vectors revealed a weak interaction with PERV Env p15E (TM) antibodies (diamonds), while incubation with Env gp70(B) (SU) antibodies (circles) caused
a neutralization effect of approximately 25%. (C–E) Results of FACS analyses of indicator cells (293) incubated with pseudotype SN treated with 100 l
of antisera. (C) 293 cells treated with Env-A pseudotypes and Env gp70(B) (SU) antibodies, (D) 293 cells treated with Env-B pseudotypes and PERV Env
p15E (TM) antibodies, (E) 293 cells treated with Env-B pseudotypes and Env gp70(B) (SU) antibodies.
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Neutralization assay
PERV pseudotype vectors were generated according to
established methods (Cosset et al., 1995) using commercial
transfer vector pEL-GFP-N1 (Clontech) with env-A and
env-B expression vectors based on pFBMoALF (kindly
provided by Y. Takeuchi) on producer cell line 293g/p (G.
Nolan, http://cmgm.stanford.edu/micro/fac/nolan). To test
for neutralizing antibodies, cell free pseudotype-containing
supernatants (SN) (final volume of 1 ml) were mixed with
different amounts of antiserum (10 l to 100 l) and incu-
bated for 1 h at room temperature. Subsequently, the mix-
tures were transferred to susceptible indicator cells (cell line
293) and transduction efficiency was determined after an
incubation period of 24 h by FACS analysis.
Nucleotide sequence accession numbers
Sequences used for homology analyses are PERV-B(33)
(AJ133816), GaLV (NC_001885), MoMLV (NC_001501),
and FeLV (NC_001940).
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